Login to Your Account



Clinic Roundup


Wednesday, November 9, 2011
• Celldex Therapeutics Inc., of Needham, Mass., initiated a Phase I study of CDX-1127 in patients with selected malignant solid tumors or hematologic cancers. A human monoclonal antibody that binds CD27, a co-stimulatory molecule on T cells, CDX-1127 is designed to activate patients' immune cells against their cancer. The Phase I study will test five escalating doses of CDX-1127 to determine dosing for future trials. The multisite, U.S. study will enroll about 30 patients in each of two arms – solid tumors or lymphomas/leukemias.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription